Clinical Trials on Multiple Erythema Migrans in Belgium

Total 432 results

Sanofi

Completed

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients (TERI-PRO)

Multiple Sclerosis

Finland, Belgium, Spain, Chile, Norway, Italy, United States, Austria, Canada, France, Germany, Greece, Sweden, United Kingdom
Sanofi

Completed

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

Multiple Sclerosis

Belgium, United States, Australia, Austria, Belarus, Canada, Chile, China, Czech Republic, Estonia, France, Germany, Greece, Mexico, Netherlands, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Thailand, Tunisia, Turkey, Ukraine, United...
University Hospital, Toulouse
Celgene; Intergroupe Francophone du Myelome

Completed

Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)

Myeloma

France, Belgium, Switzerland
Pfizer

Active, not recruiting

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Multiple Myeloma

United States, Canada, Spain, Belgium, United Kingdom, Australia, Japan, France, Germany, Poland
Janssen-Cilag Ltd.
Legend Biotech

Completed

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

Multiple Myeloma

Belgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland
Celgene

Completed

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Multiple Myeloma

Canada, Denmark, Australia, Belgium, France, Germany, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom, Czechia, Greece
Celgene

Completed

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM (ARUMM)

Multiple Myeloma

France, Italy, Spain, Belgium, Greece
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney Disease (ARPKD)

United States, Belgium, Spain, Germany, United Kingdom, Poland
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI); FDA Office of Orphan Products... and other collaborators

Completed

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network

Marfan Syndrome

United States, Canada, Belgium
Biogen

Terminated

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) (AFFINITY)

Multiple Sclerosis

United States, Italy, Spain, Belgium, Germany, Switzerland, Australia, Hungary, France, Poland, United Kingdom, Czechia, Israel, Canada, Netherlands
Hoffmann-La Roche

Active, not recruiting

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

Multiple Sclerosis

United States, Spain, Austria, Czechia, Italy, Hungary, Australia, Portugal, Serbia, Canada, Germany, United Kingdom, Poland, Romania, Croatia, Israel, Belgium, Bulgaria, Estonia, Switzerland, Mexico, Lithuania, New Zealand, France, Slo... and more
Astellas Pharma Inc

Completed

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)

Multiple Sclerosis | Spinal Cord Diseases | Neurogenic Bladder

Australia, France, Belgium, Germany, Netherlands, Italy, Spain, United Kingdom, Hungary, Czechia, Russian Federation
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

Multiple Myeloma

United States, Netherlands, Belgium, Korea, Republic of, United Kingdom, Sweden, Denmark, Italy, Japan, Germany, France, Spain, Australia, Israel, Poland, Greece
Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

United States, Japan, Norway, Spain, Sweden, Canada, Belgium, France, Germany, Brazil, Finland, Argentina, Czechia
Otsuka Pharmaceutical Development & Commercialization...

Recruiting

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)

United States, United Kingdom, Belgium, Poland, France, Germany, Italy
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

Canada, United States, France, Italy, United Kingdom, Germany, Belgium, Netherlands, Spain, Sweden, China
Celgene

Completed

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma (STRATUS)

Multiple Myeloma

Netherlands, Spain, Belgium, Austria, Switzerland, Italy, Germany, France, Ireland, United Kingdom, Denmark, Finland, Portugal, Turkey, Poland, Estonia, Greece, Norway, Slovakia, Sweden
Janssen Research & Development, LLC

Terminated

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Multiple Myeloma

Canada, United States, Belgium, Poland, Italy, France, Spain, Brazil, Russian Federation, Denmark, Greece, Germany, Netherlands
Stichting European Myeloma Network
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Multiple Myeloma

Netherlands, United States, Spain, Belgium, France, Italy, Germany, Japan, Canada, Australia, Sweden, Israel, United Kingdom, Czechia, Greece, Switzerland, Norway
Celgene

Active, not recruiting

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Multiple Myeloma

Netherlands, Belgium, Denmark, Germany, United Kingdom, France, Norway, Spain, Austria, Ireland, Italy, Sweden
Janssen Research & Development, LLC

Completed

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, France, Poland, United Kingdom, Belgium, Spain, Germany, Portugal, Bulgaria, Romania, Netherlands, Greece, Canada, Russian Federation, Hungary, Brazil, Slovakia, Czechia
Celgene Corporation

Completed

A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, United Kingdom, Italy, Switzerland, Bulgaria, Poland, Ukraine, Belgium, Germany, Hungary, Ireland, Israel, Russian Federation
Clementia Pharmaceuticals Inc.

Terminated

An Efficacy and Safety Study of Palovarotene for the Treatment of MO (MO-Ped)

Exostoses, Multiple Hereditary

United States, Spain, Canada, Japan, Italy, Portugal, United Kingdom, Turkey, Australia, Belgium, France, Netherlands
Millennium Pharmaceuticals, Inc.

Completed

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Spain, Israel, United Kingdom, Germany, Austria, Belgium, France, Italy, Ireland, Netherlands, Sweden
Oncopeptides AB

Terminated

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)

Multiple Myeloma

United States, Austria, Belgium, Czechia, Denmark, Estonia, France, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom
pharmaand GmbH

Completed

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma (PANORAMA_3)

Multiple Myeloma

Canada, Spain, United States, Czechia, Turkey, France, Sweden, Korea, Republic of, Thailand, Belgium, Greece, Germany, Hungary, Russian Federation, Italy, Poland, Australia, Lebanon, Portugal, Norway, Brazil, Netherlands
Amgen

Completed

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

Multiple Myeloma

Belgium, Austria, Czechia, Greece, Italy, France, Romania, Netherlands, Israel, Bulgaria, Norway
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Germany, Korea, Republic of, Belgium, Israel, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Japan, Czechia, Brazil, Netherlands, Poland, Portugal, Switzerland, Norway, Greece, China, Canada
Celgene

Completed

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study (NIMBUS)

Multiple Myeloma

United States, Netherlands, Canada, Belgium, United Kingdom, Australia, Denmark, Germany, Spain, Switzerland, France, Italy, Greece, Russian Federation, Sweden, Czechia
Novartis Pharmaceuticals

Withdrawn

Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

Basal Cell Carcinoma

Greece, Switzerland, Germany, United Kingdom, Belgium, Canada, Czechia, Finland, Italy, Spain
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Canada, Spain, Sweden, Germany, Australia, Netherlands, France, Argentina, Brazil, Denmark, Greece, Poland, Ireland, Hungary, Portugal, F... and more
Genzyme, a Sanofi Company

Terminated

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD)

Polycystic Kidney, Autosomal Dominant

Belgium, Germany, Czechia, United States, Italy, Poland, Argentina, Australia, Austria, Canada, China, Denmark, France, Israel, Japan, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Taiwan, Turkey, United Kingdom
GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
Takeda

Completed

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Multiple Myeloma

United States, Spain, United Kingdom, Belgium, Taiwan, Italy, Israel, China, Turkey, Germany, Greece, Mexico, Colombia, France, Brazil
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (MonumenTAL-1)

Hematological Malignancies

United States, Belgium, Korea, Republic of, China, Germany, Israel, Netherlands, Japan, Spain, France, Poland
Intergroupe Francophone du Myelome
Janssen Research & Development, LLC; HOVON - Dutch Haemato-Oncology Association

Active, not recruiting

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)

Multiple Myeloma

Netherlands, France, Belgium
Janssen Research & Development, LLC

Completed

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

Australia, France, Poland, United Kingdom, United States, Spain, Israel, Portugal, South Africa, Canada, Netherlands, Belgium, Singapore, Russian Federation, Czech Republic, Argentina, Austria
Amgen

Completed

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (ARROW)

Multiple Myeloma

Canada, Denmark, Finland, France, Italy, Spain, Sweden, United Kingdom, Czechia, Poland, United States, Belgium, Hungary, New Zealand, Australia, Germany, Japan, Greece, Norway, Romania
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
GlaxoSmithKline

Active, not recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Multiple Myeloma

Australia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
Karyopharm Therapeutics Inc

Active, not recruiting

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

Multiple Myeloma

United States, United Kingdom, Australia, Israel, Canada, Belgium, Austria, Czechia, Serbia, India, France, Italy, Russian Federation, Bulgaria, Germany, Greece, Hungary, Poland, Romania, Spain, Ukraine
Millennium Pharmaceuticals, Inc.

Completed

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Multiple Myeloma

United States, United Kingdom, Canada, Israel, France, Austria, Belgium, Germany, Ireland, Italy, Netherlands, Spain, Sweden
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
Millennium Pharmaceuticals, Inc.

Completed

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, France, Korea, Republic of, Canada, Belgium, New Zealand, Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) (EXIST-1)

Tuberous Sclerosis | Subependymal Giant Cell Astrocytoma

United States, Belgium, Canada, Germany, Italy, Russian Federation, Netherlands, Poland, Australia, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, Denmark, United States, Spain, Australia, Japan, France, Korea, Republic of, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, United Kingdom, Czechia, Germany, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Bristol-Myers Squibb
AbbVie

Completed

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Multiple Myeloma

United States, Australia, Austria, Belgium, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland, Turkey, United Kingdom

Clinical Trials on Multiple Erythema Migrans in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations